SecBot SecBot
6-K ·Filed Aug 27, 2026

BWAY

Brainsway Ltd.
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001171843-26-005759
Notable filing: 6-K
Actionable Insight ▲ Bullish

Positive clinical data supports BrainsWay's scientific narrative and could drive adoption among clinicians treating MDD with suicidal ideation. However, the lack of FDA clearance for this specific indication limits immediate commercial impact. Monitor for any future FDA submission or label expansion announcements. The 20-F (filed April 2026) showed strong revenue growth of 27% to $52.2M, providing fundamental support alongside this clinical catalyst.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$14.40
T+0 close · Aug 27, 2026 · via day close
Latest settled
−8.26%
T+20 · $13.21 · next T+60 in 4d
Vs SPY
−7.76%
α at T+20
Latest observation
−21.59%
T+54 · FF3 residual α
  1. T+0 · Aug 27 $14.40entry
  2. T+1 · 3mo ago −0.69%α −0.47% · $14.30
  3. T+5 · 2mo ago +0.76%α +0.50% · $14.51
  4. T+20 · 7w ago −8.26%α −7.76% · $13.21
  5. T+56 · todayOpen
  6. T+60 · in 4d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BrainsWay announced publication of a peer-reviewed secondary analysis in the Journal of Affective Disorders showing a 70% relative reduction in suicidal ideation among MDD patients treated with Deep TMS (from 22.5% to 6.7% over 6 weeks). The data adds to a growing body of 2026 research supporting Deep TMS for suicidality, though the device is not FDA-cleared for this indication. The filing is a clinical-data update without financial figures, providing incremental positive evidence for label expansion potential.

Key Facts

  • 70% relative reduction in patients with suicidal ideation (SSI>0) from 22.5% at baseline to 6.7% after 6 weeks of Deep TMS
  • Median time to improvement in suicidality was 10 days with SWIFT accelerated protocol vs 13 days with standard protocol (statistically significant)
  • Data published in Journal of Affective Disorders as secondary analysis of prior multisite randomized trial that supported FDA clearance of SWIFT in September 2025
  • Deep TMS is not FDA-cleared for treatment or prevention of suicidal ideation or behavior

Financial Impact

No financial figures provided; potential label expansion catalyst for Deep TMS in MDD, which could expand addressable market if future FDA clearance obtained

Risk Factors

  • Secondary analysis data, not a prospective randomized trial designed for suicidality endpoint
  • Deep TMS not FDA-cleared for suicidal ideation, no near-term label expansion
  • Small sample size (89 patients) limits statistical robustness

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005759
Document: 0001171843-26-005759-index-headers.html0001171843-26-005759
Document: 0001171843-26-005759-index.html0001171843-26-005759
Document: 0001171843-26-005759.txt0001171843-26-005759

US Market Status

Market Closed · Opens Tue (17h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026